The Shifting Field of Stem Cell Regulations
Recent FDA Hearings Sparked by Concerns Over Growth of Clinics Offering Unapproved Therapies to Consumers
Enhancing Graduate and Postdoc Education for a Sustainable Workforce
Ph.D.-Trained Biomedical Scientists Can No Longer Count on Finding Academic Positions Upon Graduation
Unlucky 13: Top Clinical Trial Failures of 2016
In Missing Primary Endpoints, These Drugs Touched Off Stock Selloff, Layoffs, and Worse
Supplement: Therapeutic Cancer Vaccine Roundup
Individualized Cell Therapies Come with a Unique Set of Bioprocess Requirements
For full access to this article login to GEN Select now.
Tissue Engineering Revenues Rise
- More than half (52%) of the companies comprising the tissue engineering (TE) and stem cell industries are revenue-generating, compared to about 21% four years ago, according to an analysis published in Tissue Engineering Part B . Of those companies, 31% having commercial products and 21% are service-based; another 30% ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.